Carcinoembryonic antigen and interferon as tumor markers in breast cancer

1983 ◽  
Vol 22 (4) ◽  
pp. 254-256 ◽  
Author(s):  
Yoav Horn ◽  
Dalia Hacohen ◽  
Jacob L. Zeidman ◽  
Natalio Walach ◽  
Sally Sharf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers

scholarly journals Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

2010 ◽  
Vol 56 (7) ◽  
pp. 1148-1157 ◽  
Author(s):  
Rafael Molina ◽  
Jose M Auge ◽  
Blanca Farrus ◽  
Gabriel Zanón ◽  
Jaume Pahisa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Primary Breast Cancer ◽  
Disease Free Survival ◽  
Carbohydrate Antigen ◽  
Nodal Involvement ◽  
Total Group ◽  
Ca 15.3

Abstract Background: The utility of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) as prognostic factors in primary breast cancer is unclear. Methods: We prospectively studied CEA and CA 15.3 in the sera of 2062 patients with untreated primary breast cancer diagnosed between 1984 and 2008. Results: Increased CEA (>5 μg/L) and CA 15.3 (>30 kU/L) concentrations were found in 12.7% and 19.6% of the patients, respectively, and 1 or both tumor markers were increased in 28% (570 of 2062). Increases in each tumor marker correlated with larger tumor sizes and nodal involvement. Tumor size, estrogen receptor (ER), and CEA were independent prognostic factors by multivariate analysis in the total group [disease free survival (DFS) and overall survival (OS)] as well as in node-positive (NP) and node-negative (NN) patients. Nodal involvement and histological grade were independent prognostic factors in the total group as well as in NP patients. By contrast, adjuvant treatment and CA 15.3 were independent prognostic factors only in NN patients (DFS and OS). All patients with CEA >7.5 μg/L had recurrence during follow-up. Use of both tumor markers allowed discrimination of the groups of risk in T1 NN patients: 56.3% of recurrences were seen when 1 or both tumor markers were increased, whereas only 9.4% of recurrences were seen in T1 NN patients without increases of either marker. Conclusions: CEA and CA 15.3 are useful prognostic factors in NP and NN breast cancer patients. CEA >7.5 μg/L is associated with a high probability of subclinical metastases.

scholarly journals THE SIGNIFICANCE OF CEA AND CA15-3 IN EARLY BREAST CANCER ITS ASSOCIATION WITH CLINICO PATHOLOGICAL CHARACTERISTICS A SINGLE-CENTER STUDY IN MADINAH, SAUDI ARABIA

2020 ◽  
Vol 8 (11) ◽  
pp. 1082-1087
Author(s):  
Nasser Mulla ◽  
◽  
Yara Bin Saad ◽  
Jamlaa Alharbi ◽  
Salwa Alalwi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Primary Tumor ◽  
Elevated Serum ◽  
Tumor Grade ◽  
Serum Levels ◽  
Clinicopathological Characteristics ◽  
Cancer Antigen ◽  
Cancer Types

Background and Aims: The utility of measuring carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in patients with breast cancer remains controversial. The present study aims to investigate the association between tumor markers [cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)] and clinicopathological characteristics. Methods: Serum preoperative CEA and CA 15-3 concentration levels were measured in a total of 135 breast cancer patients.The association of tumor markers levels with clinicopathological characteristics were analyzed. Results: Elevated serum levels of CEA and CA15-3 were identified in 26 (19.26%) and 20 (14.8%) patients, respectively. Increased CEA levels were not associated with age, histological type, tumor size, tumor grade, breast cancer stages, or breast cancer types. CA15-3 levels were positively correlated with the size of the primary tumor (P<0.026) but had no significant correlation with the other factors. Conclusions: The elevation of CA 15-3 was positively correlated with the size of the primary tumor.

scholarly journals Assessing the Effect of Carcinoembryonic Antigen Tumor Marker Progression on Survival after Mastectomy in Patients With Breast Cancer: A Joint Survival Longitudinal Approach

2020 ◽  
Vol 9 (3) ◽  
pp. 111-115
Author(s):  
Amal Saki Malehi ◽  
Maedeh Raissizadeh ◽  
Shima Younespour ◽  
Mohammad Seghatoleslami ◽  
Mehran Hosseinzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Joint Modeling ◽  
Serum Tumor Markers ◽  
Significant Difference ◽  
Serum Cea ◽  
Southwest Of Iran ◽  
Over Time

Background: Breast cancer remains the most prevalent neoplasm in women, with more than 450000 deaths each year, worldwide. In cancer researches, several factors such as serum tumor markers have an important role in screening, treatment, and recurrence of the disease. Carcinoembryonic antigen (CEA) is one of the most widely used serum tumor markers in the clinical evaluation of patients with breast cancer. This study aimed to evaluate whether increasing serum CEA levels is an indicator of breast cancer patient’s survival or not. Materials and Methods: This retrospective study was done at Hematology Department of Shafa Hospital of Ahvaz, southwest of Iran. Only those patients who had mastectomy during 2006-2014 and regularly referred to the hospital were included. The joint survival longitudinal model was applied to analyze the data. JM package in R software was used for joint modeling analysis. Results: The five-year survival rate was 73.0%. Age and follow-up time were associated with CEA tumor marker values. Higher age is associated with higher CEA values over time (P=0.0156). There was a significant linear increasing trend in CEA values over time (P=0.0465). There was a significant difference between patients with and without nodal involvement (HR [95% CI]: 1.880 [1.330- 5.565]; P=0.0298). There was a positive correlation between CEA tumor marker levels and death (HR [95% CI]: 2.770 [1.369-5.603]; P=0.0046). Conclusion: Higher age is associated with higher CEA values over time. The involvement of lymph nodes increases the hazard of death. Death is more likely to occur in patients with higher CEA tumor marker levels.

scholarly journals The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer

Cureus ◽  
2021 ◽  
Author(s):  
Maimoona Khushk ◽  
Adil Khan ◽  
Abdur Rehman ◽  
Sehrish Sheraz ◽  
Yar Muhammad Tunio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Cancer Antigen

Serum Tumor Markers in Stage I-II Breast Cancer

2016 ◽  
Vol 12 (3) ◽  
pp. 285-289 ◽  
Author(s):  
Renato Tozzoli ◽  
Federica D';Aurizio ◽  
Flavio Falcomer ◽  
Stefano M.M. Basso ◽  
Franco Lumachi
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Stage I ◽  
Serum Tumor Markers

scholarly journals Clinical impact of PTEN methylation status as a prognostic marker for breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Amal Ramadan ◽  
Maha Hashim ◽  
Amr Abouzid ◽  
Menha Swellam
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Prognostic Marker ◽  
Methylation Status ◽  
Clinical Impact ◽  
Breast Cancer Patients ◽  
Duct Carcinoma ◽  
Cancer Group ◽  
And Control

Abstract Background Aberrant DNA methylation of phosphatase and tensin homolog (PTEN) gene has been found in many cancers. The object of this study was to evaluate the clinical impact of PTEN methylation as a prognostic marker in breast cancer. The study includes 153 newly diagnosed females, and they were divided according to their clinical diagnosis into breast cancer patients (n = 112) and females with benign breast lesion (n = 41). A group of healthy individuals (n = 25) were recruited as control individuals. Breast cancer patients were categorized into early stage (0–I, n = 48) and late stage (II–III, n = 64), and graded into low grade (I–II, n = 42) and high grade (III, n = 70). Their pathological types were invasive duct carcinoma (IDC) (n = 66) and duct carcinoma in situ (DCI) (n = 46). Tumor markers (CEA and CA15.3) were detected using ELISA. DNA was taken away from the blood, and the PTEN promoter methylation level was evaluated using the EpiTect Methyl II PCR method. Results The findings revealed the superiority of PTEN methylation status as a good discriminator of the cancer group from the other two groups (benign and control) with its highest AUC and increased sensitivity (96.4%) and specificity (100%) over tumor markers (50% and 84% for CEA and 49.1% and 86.4% for CA15.3), respectively. The frequency of PTEN methylation was 96.4% of breast cancer patients and none of the benign and controls showed PTEN methylation and the means of PTEN methylation (87 ± 0.6) were significantly increased in blood samples of breast cancer group as compared to both benign and control groups (25 ± 0.7 and 12.6 ± 0.3), respectively. Methylation levels of PTEN were higher in the blood of patients with ER-positive than in patients with ER-negative cancers (P = 0.007) and in HER2 positive vs. HER2 negative tumors (P = 0.001). The Kaplan-Meier analysis recognizes PTEN methylation status as a significant forecaster of bad progression-free survival (PFS) and overall survival (OS), after 40 months follow-up. Conclusions PETN methylation could be supposed as one of the epigenetic aspects influencing the breast cancer prognosis that might foretell more aggressive actions and worse results in breast cancer patients.

Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value

Tumor Biology ◽  
2010 ◽  
Vol 31 (3) ◽  
pp. 171-180 ◽  
Author(s):  
Rafael Molina ◽  
Jose M. Augé ◽  
Jose M. Escudero ◽  
Xavier Filella ◽  
Gabriel Zanon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Prognostic Value ◽  
Ca 15.3 ◽  
Her 2

Carcinoembryonic antigen in breast cancer

Cancer ◽  
1978 ◽  
Vol 42 (S3) ◽  
pp. 1520-1526 ◽  
Author(s):  
Robert E. Myers ◽  
Donald J. Sutherland ◽  
James W. Meakin ◽  
John A. Kellen ◽  
Dina G. Malkin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen
Sign in / Sign up

Export Citation Format

Share Document